Defining the role of anti-angiogenesis agents

University of California-San Francisco researchers and colleagues have dissected different stages of tumor formation to show that different angiogenesis inhibitors are more or less efficacious depending on the stage of cancer they were used to treat.

The results, published last week in Science, point out that the optimum clinical use of anti-angiogenic compounds will not likely be as a universal magic bullet, but rather as part of a fine-tuned multi-drug approach to treating patients with cancer (see B13).